BFEC
RXST icon

Benjamin F. Edwards & Company’s RxSight RXST Stock Holding History

Benjamin F. Edwards & Company’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$5K Sell
81
-25
-24% -$1.43K ﹤0.01% 1895
2024
Q1 		$5K Sell
106
-16
-13% -$785 ﹤0.01% 1882
2023
Q4 		$5K Buy
+122
New +$3.58K ﹤0.01% 1865

Other funds holding RXST

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Benjamin F. Edwards & Company's RXST Position: Q2 2024 in Review

Benjamin F. Edwards & Company reduced its RxSight (RXST) stake by 24% in Q2 2024, selling an estimated $1.43K and leaving 81 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #1895.

Benjamin F. Edwards & Company first reported a position in RXST in Q4 2023 and has held it in 3 quarters since. 228 funds tracked by Wall St. Rank hold RXST as of Q2 2024.

  • Benjamin F. Edwards & Company held 81 shares of RxSight worth $5K as of Q2 2024.
  • Benjamin F. Edwards & Company sold 25 RxSight shares in Q2 2024, an estimated $1.43K.
  • RxSight made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #1895 holding.
  • Benjamin F. Edwards & Company first reported a position in RxSight in Q4 2023 and has held it in 3 quarters since.
  • 228 funds tracked by Wall St. Rank held RxSight as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.